Equities researchers at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a report issued on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Shares of NASDAQ TTNP opened at $3.84 on Friday. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80. The firm has a market capitalization of $3.51 million, a P/E ratio of -0.74 and a beta of 1.27. The company’s 50 day simple moving average is $3.72 and its 200 day simple moving average is $3.69.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- Transportation Stocks Investing
- Monster Beverage Stock: Short Report Risks vs Upside Potential
- Roth IRA Calculator: Calculate Your Potential Returns
- Onsemi Stock Confirms Bottom, But What’s the Upside?
- Top Stocks Investing in 5G Technology
- 3 Tech Leaders Announce Buybacks Totaling $85 Billion
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
